Literature DB >> 10720536

Monocyte-endothelial cell coculture enhances infection of endothelial cells with Chlamydia pneumoniae.

T M Lin1, L A Campbell, M E Rosenfeld, C C Kuo.   

Abstract

To determine the mechanism(s) by which Chlamydia pneumoniae homes to and establishes persistent infection in atheromatous lesions, the effect of the interaction of monocytes/macrophages (U937 cells) with human umbilical vein endothelial cells (HUVECs) and transformed human arterial endothelial cells (HMEC-1s) on the susceptibility of endothelial cells to infection with C. pneumoniae was investigated. Infection was enhanced 4.7-fold (HUVECs) and 4.4-fold (HMEC-1s) after coculture at monocyte-to-endothelial cell ratios of 5 and 2.5, respectively. U937 cells also directly transmitted infection to the endothelial cells, and addition of U937 cell-conditioned media dose-dependently enhanced the infectivity 2.0- to 2.5-fold. The stimulation of infectivity was specific to endothelial cells, because coculturing of monocytes with epithelial cells did not enhance the susceptibility of epithelial cells to infection. The susceptibility of endothelial cells to infection with C. trachomatis and C. psittaci was not enhanced by the monocyte-derived factor(s).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720536     DOI: 10.1086/315349

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon.

Authors:  L G Pantoja; R D Miller; J A Ramirez; R E Molestina; J T Summersgill
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Chlamydia pneumoniae uses the mannose 6-phosphate/insulin-like growth factor 2 receptor for infection of endothelial cells.

Authors:  Mirja Puolakkainen; Cho-Chou Kuo; Lee Ann Campbell
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Chlamydia pneumoniae--induced macrophage foam cell formation is mediated by Toll-like receptor 2.

Authors:  Fei Cao; Antonio Castrillo; Peter Tontonoz; Fabio Re; Gerald I Byrne
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

Review 4.  Dissemination of Chlamydia pneumoniae to the vessel wall in atherosclerosis.

Authors:  Satoru Hirono; Grant N Pierce
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

5.  Chlamydia pneumoniae growth inhibition in cells by the steroid receptor antagonist RU486 (mifepristone).

Authors:  Hiroyuki Yamaguchi; Shigeru Kamiya; Tomonori Uruma; Takako Osaki; Haruhiko Taguchi; Tomoko Hanawa; Minoru Fukuda; Hayato Kawakami; Hajime Goto; Herman Friedman; Yoshimasa Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

6.  Increased incidence of cytomegalovirus but not Chlamydia pneumoniae in atherosclerotic lesions of arteries of lower extremities from patients with diabetes mellitus undergoing amputation.

Authors:  T-M Lin; W-j Chen; H-Y Chen; P-W Wang; H-L Eng
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

7.  Amalgamation of Chlamydia pneumoniae inclusions with lipid droplets in foam cells in human atherosclerotic plaque.

Authors:  Yuri V Bobryshev; Murray C Killingsworth; Dihn Tran; Reginald Lord
Journal:  Virchows Arch       Date:  2008-06-06       Impact factor: 4.064

8.  The effect of Chlamydia pneumoniae on the expression of peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells.

Authors:  Yong-Hwan Kim; Si-Young Choi; Jong-Hui Suh; Tae-Kyun Kim; Ki-Bae Seung; Young-Pil Wang; Kiyuk Chang
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

9.  Human blood monocytes support persistence, but not replication of the intracellular pathogen C. pneumoniae.

Authors:  Tanja Buchacher; Herbert Wiesinger-Mayr; Klemens Vierlinger; Beate M Rüger; Gerold Stanek; Michael B Fischer; Viktoria Weber
Journal:  BMC Immunol       Date:  2014-12-09       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.